Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis
Identifieur interne : 001511 ( Main/Exploration ); précédent : 001510; suivant : 001512Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis
Auteurs : Pieter C. Goeminne [Belgique] ; Patrick Verschueren [Belgique] ; Hans Scheers [Belgique] ; Lieven J. Dupont [Belgique]Source :
- Clinical Rheumatology [ 0770-3198 ] ; 2012-02-01.
English descriptors
- KwdEn :
Abstract
Abstract: Rheumatic diseases as well as inflammatory bowel disease (IBD) have been associated with the occurrence of non-cystic fibrosis bronchiectasis (NCFB). There are few data on NCFB and adverse events from immunosuppressive or biological response modifier therapy in patients with rheumatoid arthritis (RA) or IBD and NCFB. We identified 37 patients with NCFB and rheumatic disease, and nine patients with inflammatory bowel disease that received immunomodulatory treatment. We retrospectively analysed adverse pulmonary events. In nine patients with RA, the association between disease activity score (DAS) and spirometry was analysed in a small cohort study. Pulmonary side effects occurred in 50% of patients, most commonly respiratory infections, and resulted in a change of immunomodulatory treatment in 37% of patients. Spirometry and exacerbation rate was not different in NCFB patients with RA or IBD as compared with NFCB due to other causes. The incidence of pulmonary adverse events was highest in patients treated with conventional immunomodulatory treatment, especially methotrexate, as compared with patients with NCFB treated with newer biological therapies. Three patients were started on azithromycin because of recurrent bronchitis and had no events afterwards. Serial assessment of DAS and spirometry showed that a rise in DAS was associated with lung function decline and vice versa. Currently used immunosuppressive drugs can be used in NCFB albeit under close follow-up. The role of azithromycin for infection prevention needs further research. An association between DAS and lung function was shown.
Url:
DOI: 10.1007/s10067-011-1849-4
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A69
- to stream Istex, to step Curation: 000A69
- to stream Istex, to step Checkpoint: 000487
- to stream Main, to step Merge: 001513
- to stream Main, to step Curation: 001511
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis</title><author><name sortKey="Goeminne, Pieter C" sort="Goeminne, Pieter C" uniqKey="Goeminne P" first="Pieter C." last="Goeminne">Pieter C. Goeminne</name></author><author><name sortKey="Verschueren, Patrick" sort="Verschueren, Patrick" uniqKey="Verschueren P" first="Patrick" last="Verschueren">Patrick Verschueren</name></author><author><name sortKey="Scheers, Hans" sort="Scheers, Hans" uniqKey="Scheers H" first="Hans" last="Scheers">Hans Scheers</name></author><author><name sortKey="Dupont, Lieven J" sort="Dupont, Lieven J" uniqKey="Dupont L" first="Lieven J." last="Dupont">Lieven J. Dupont</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:81777A6FECC1BDF46B23843403FDD34F01E3449D</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1007/s10067-011-1849-4</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-3XBW92HC-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000A69</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A69</idno><idno type="wicri:Area/Istex/Curation">000A69</idno><idno type="wicri:Area/Istex/Checkpoint">000487</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000487</idno><idno type="wicri:doubleKey">0770-3198:2011:Goeminne P:safety:of:immunomodulatory</idno><idno type="wicri:Area/Main/Merge">001513</idno><idno type="wicri:Area/Main/Curation">001511</idno><idno type="wicri:Area/Main/Exploration">001511</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis</title><author><name sortKey="Goeminne, Pieter C" sort="Goeminne, Pieter C" uniqKey="Goeminne P" first="Pieter C." last="Goeminne">Pieter C. Goeminne</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Pneumology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Respiratory Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Belgique</country></affiliation></author><author><name sortKey="Verschueren, Patrick" sort="Verschueren, Patrick" uniqKey="Verschueren P" first="Patrick" last="Verschueren">Patrick Verschueren</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Rheumatology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Belgique</country></affiliation></author><author><name sortKey="Scheers, Hans" sort="Scheers, Hans" uniqKey="Scheers H" first="Hans" last="Scheers">Hans Scheers</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Pneumology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Belgique</country></affiliation></author><author><name sortKey="Dupont, Lieven J" sort="Dupont, Lieven J" uniqKey="Dupont L" first="Lieven J." last="Dupont">Lieven J. Dupont</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Pneumology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Belgique</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="ISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>London</pubPlace><date type="published" when="2012-02-01">2012-02-01</date><biblScope unit="volume">31</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="367">367</biblScope><biblScope unit="page" to="373">373</biblScope></imprint><idno type="ISSN">0770-3198</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0770-3198</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biologic response modifiers</term><term>Bronchiectasis</term><term>Inflammatory bowel disease</term><term>Non-cystic fibrosis</term><term>Rheumatic disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Rheumatic diseases as well as inflammatory bowel disease (IBD) have been associated with the occurrence of non-cystic fibrosis bronchiectasis (NCFB). There are few data on NCFB and adverse events from immunosuppressive or biological response modifier therapy in patients with rheumatoid arthritis (RA) or IBD and NCFB. We identified 37 patients with NCFB and rheumatic disease, and nine patients with inflammatory bowel disease that received immunomodulatory treatment. We retrospectively analysed adverse pulmonary events. In nine patients with RA, the association between disease activity score (DAS) and spirometry was analysed in a small cohort study. Pulmonary side effects occurred in 50% of patients, most commonly respiratory infections, and resulted in a change of immunomodulatory treatment in 37% of patients. Spirometry and exacerbation rate was not different in NCFB patients with RA or IBD as compared with NFCB due to other causes. The incidence of pulmonary adverse events was highest in patients treated with conventional immunomodulatory treatment, especially methotrexate, as compared with patients with NCFB treated with newer biological therapies. Three patients were started on azithromycin because of recurrent bronchitis and had no events afterwards. Serial assessment of DAS and spirometry showed that a rise in DAS was associated with lung function decline and vice versa. Currently used immunosuppressive drugs can be used in NCFB albeit under close follow-up. The role of azithromycin for infection prevention needs further research. An association between DAS and lung function was shown.</div></front></TEI><affiliations><list><country><li>Belgique</li></country></list><tree><country name="Belgique"><noRegion><name sortKey="Goeminne, Pieter C" sort="Goeminne, Pieter C" uniqKey="Goeminne P" first="Pieter C." last="Goeminne">Pieter C. Goeminne</name></noRegion><name sortKey="Dupont, Lieven J" sort="Dupont, Lieven J" uniqKey="Dupont L" first="Lieven J." last="Dupont">Lieven J. Dupont</name><name sortKey="Dupont, Lieven J" sort="Dupont, Lieven J" uniqKey="Dupont L" first="Lieven J." last="Dupont">Lieven J. Dupont</name><name sortKey="Goeminne, Pieter C" sort="Goeminne, Pieter C" uniqKey="Goeminne P" first="Pieter C." last="Goeminne">Pieter C. Goeminne</name><name sortKey="Goeminne, Pieter C" sort="Goeminne, Pieter C" uniqKey="Goeminne P" first="Pieter C." last="Goeminne">Pieter C. Goeminne</name><name sortKey="Scheers, Hans" sort="Scheers, Hans" uniqKey="Scheers H" first="Hans" last="Scheers">Hans Scheers</name><name sortKey="Scheers, Hans" sort="Scheers, Hans" uniqKey="Scheers H" first="Hans" last="Scheers">Hans Scheers</name><name sortKey="Verschueren, Patrick" sort="Verschueren, Patrick" uniqKey="Verschueren P" first="Patrick" last="Verschueren">Patrick Verschueren</name><name sortKey="Verschueren, Patrick" sort="Verschueren, Patrick" uniqKey="Verschueren P" first="Patrick" last="Verschueren">Patrick Verschueren</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001511 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001511 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:81777A6FECC1BDF46B23843403FDD34F01E3449D
|texte= Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis
}}
| This area was generated with Dilib version V0.6.33. |  |